61,252 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Caprock Group LLC

Caprock Group LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 61,252 shares of the company's stock, valued at approximately $7,293,000.

Other large investors also recently modified their holdings of the company. Pathstone Holdings LLC lifted its position in Novo Nordisk A/S by 0.3% during the third quarter. Pathstone Holdings LLC now owns 290,229 shares of the company's stock worth $34,558,000 after acquiring an additional 734 shares during the last quarter. Aviance Capital Partners LLC lifted its holdings in Novo Nordisk A/S by 4.7% during the 3rd quarter. Aviance Capital Partners LLC now owns 17,091 shares of the company's stock worth $2,035,000 after purchasing an additional 770 shares during the last quarter. Baron Wealth Management LLC boosted its stake in Novo Nordisk A/S by 18.8% in the 3rd quarter. Baron Wealth Management LLC now owns 3,224 shares of the company's stock valued at $384,000 after purchasing an additional 510 shares during the period. Nixon Peabody Trust Co. bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $247,000. Finally, Semus Wealth Partners LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $420,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE:NVO traded up $2.83 on Tuesday, hitting $102.65. The company had a trading volume of 5,777,868 shares, compared to its average volume of 4,480,769. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $460.62 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 1.31 and a beta of 0.42. The firm has a 50 day moving average of $117.40 and a two-hundred day moving average of $129.27.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent research reports. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Buy" and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.